We sought to determine the feasibility of conducting percutaneous coronary intervention ( PCI ) in high-risk acute coronary syndrome ( ACS ) patients utilising the REG1 system consisting of pegnivacogin , an aptameric factor IXa inhibitor , and its controlling agent anivamersen .